Score card will show final sale figure the rest will be forgotten in time. Started from nothing sold for $400m
TLS Telstra to boost phone plan prices despite inflation – and despite claiming they wouldn't 2 months ago
MSB Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%